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Abstract
Objectives: evaluation of the effectiveness of a new structured diabetes teaching and treatment programme (DTTP) with
speciﬁc didactical approaches and topics for geriatric patients with diabetes mellitus.
Design: a prospective randomised controlled multi-centre trial.
Setting and participants: a total of 155 geriatric patients were randomly admitted to either the new DTTP SGS (n = 83)
or the standard DTTP (n = 72) for insulin-treated patients with type 2 diabetes mellitus (HbA1c 8.0 ± 1.4%, age 76.2 ± 6.3
years).
Measurements: biometrical data, metabolic control, acute complications, diabetes knowledge, self-management.
Results: SGS participants showed improved levels of HbA1c 6 months after the DTTP, and less acute complications than
the standard group (P<0.009). Both groups demonstrated a good capacity for diabetes self-management and improvement in
diabetes knowledge after the DTTP (P<0.01).
Conclusion: the new SGS diabetes education programme, focusing on the learning capabilities and the particular needs of
olderpersons,iseffectiveinimprovingmetaboliccontrolandinmaintainingauto-sufﬁciencyingeriatricpatientswithdiabetes
mellitus.
Keywords: diabetes mellitus type 2, patient education, treatment and teaching programme, insulin therapy, randomised controlled
trial, elderly
Introduction
Althoughpatienteducationhasbecomeanintegralpartofall
diabetestherapyprogrammes,theelderlyareoftennotableto
competentlyfollowthevarietyoftopicscomprisingthestan-
dard treatment and teaching programmes for insulin-treated
patients with type 2 diabetes mellitus (T2DM), due to neu-
ropsychologicalandphysicaldeﬁcits[1–3].Tobalanceclinical
recommendations[3,4]andtheneedsofolderadultswithdia-
betes, a working group of the German Diabetes Association
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has developed a structured diabetes treatment and teaching
programme (DTTP) specialised for older adults with T2DM
called SGS (Strukturierte Geriatrische Schulung, structured
geriatricDTTP).Incomparisontoastandardeducationpro-
gramme [5, 6] for patients with T2DM on insulin therapy,
which has been well validated in inpatient and outpatient
cohorts in Germany [7], the new SGS programme focuses
particularly on individual therapeutic goals and maintenance
of autonomy. The aim of the present study was to evaluate
the effectiveness of the SGS DTTP for insulin-treated older
patients with diabetes mellitus, in a prospective, randomised
and controlled multi-centre trial.
The SGS DTTP for elderly patients with
diabetes
TheSGScomprisesseveneducationalclassesof45mindura-
tion. In contrast, the standard DTTP of Berger et al.[ 5 ]
for insulin therapy takes a period of 5 days with 20 h of
training. The SGS DTTP focuses less on theoretical knowl-
edge (pathophysiology, insulin dose adoption, or assessment
of carbohydrate intake) but allows a more intensive train-
ing of practical capabilities such as insulin injection, self-
monitoring and management of hypoglycaemia. The new
SGS programme takes into account the changes in learning
habits of older people (reduced short-term memory, slowed
informational processing). The programme is adapted to the
demands of older people, for example by giving instruction
more slowly and loudly, avoiding technical terms or giving
more intensive practice and using deﬁned numbers of rep-
etitions. Educational materials such as patient books and
ﬂipcharts with an adequate type size are provided. In the
SGS DTTP, a smaller class size of four to six patients is
used, whereas the standard DTTP allows up to 10 people to
participate in the education classes.
Methods
Inclusion and exclusion criteria
A total of 196 patients with insulin-treated T2DM were
screened for study participation from May 2004 until May
2005. Inclusion criteria were insulin-treated diabetes melli-
tus, at least one geriatric syndrome (such as incontinence,
reduced mobility requiring the use of assistive devices, a his-
tory of falls during the previous 2 years or cognitive dys-
function), multi-morbidity (more than two chronic diseases
besides T2DM) and age >65 years. Exclusion criteria were
strokeormyocardialinfarctionwithin2weekspriortoenrol-
ment as well as a Mini-Mental State Examination (MMSE)
below 18 points implying moderate cognitive dysfunction.
Of the 196 screened patients, 41 were excluded from statisti-
cal analysis (dropouts) because of missing data sets (n = 22)
ortheirnotﬁnishingtheDTTP(n=17).Onepatientdropped
out because of sufﬁcient metabolic control on oral antidia-
betic drug therapy.
Assessed for eligibility (t0) 
(n=196) 
Drop outs (n=41) 
Enrolment (t0) 
( n=155) 
Randomization to SGS (t1) 
(n=83) 
Randomization to Standard (t1) 
(n=72) 
Follow up Standard (t2)
(n=54)  
SGS DTTP
Follow up SGS (t2)
(n=65)   
Standard DTTP
Died (n=3)
No follow up 
Died (n=5)
No follow up 
Figure 1. Patient ﬂow.
Sample size and randomisation
According to the sample size calculation for an α set at 0.05
and a power at 1−β = 0.8, a total sample size of 102 in each
group will be needed.
Randomisation: a total of 155 patients were admitted to
one of 18 study centres in Germany, and sent randomly in
groups of four to six people to either the new SGS DTTP or
the standard DTTP for insulin-treated patients with T2DM
following Berger et al. [5]. Randomisation was performed
centrally by one study investigator. Randomisation lists were
used throughout. The study investigator received a fax of
the planned education group (with the study codes, age and
sex of the patients) and randomised the group according
to the randomisation protocol. Nine of the 18 study cen-
tres were outpatient diabetes clinics recruiting 105 study
participants (67.7%). Ten inpatient diabetes departments
recruited 50 study participants (32.3%). Eighty-three of the
155 patients who were eligible for statistical analysis were
randomly sent to the new SGS DTTP, and 72 were placed in
the standard programme (patient ﬂow, see Figure 1). Due to
delayedpatientrecruitment,dropoutrateandlimitedﬁnancial
resources, the study had to be stopped after the inclusion of
155 patients.
The ethics committee approved the study in 2003. The
study is registered at Clinical Trials.gov (NCT00391040). All
patients gave written informed consent.
The primary outcome measures were improvement of
metabolic control and self-management skills. Secondary
outcomes were incidence of acute complications, diabetes
knowledge and treatment satisfaction.
Measurements
Before (t0), immediately after (t1) and 6 months after the
DTTP(t2),outcomequalitywasmeasuredusingstandardised
methods:
391A. K. Braun et al.
Table 1. Patient characteristics at baseline visit: full sample (n = 155) and completers (n = 119)
Full sample
Full sample SGS Standard P-value
.......................................................................................................................................
Number of patients 155 83 72 –
Mean HbA1c% ± SD 8.0 ± 1.4 8.3 ± 1.5 7.6 ± 1.3 0.003
Mean age (years) ± SD 76.2 ± 6.3 75.3 ± 6.2 77.3 ± 6.1 0.75
Median diabetes duration (years) (Range) 12.5 (0–56.5) 12.5 (0–56.5) 14.5 (0.3–42.5) 0.12
Mean score MMSE ± SD 26.0 ± 3.1 26.2 ± 2.8 25.8 ± 3.3 0.41
Mean score AKT ± SD 50.9 ± 6.4 51.1 ± 4.8 50.7 ± 8.0 0.72
Female, n (%) 103 (66.5) 58 (69.9) 45 (62.5) 0.33
Completers
Completers SGS Standard P-value
Number of patients 119 65 54 –
Mean HbA1c% ± SD 8.0 ± 1.4 8.3 ± 1.5 7.7 ± 1.3 0.02
Mean age (years) 75.9 ± 6.4 74.6 ± 6.1 77.5 ± 6.3 0.79
Median diabetes duration (years) (range) 13.7 (0.03–48.5) 12.5 (0.03–48.5) 15.1 (0.3–42.5) 0.09
Mean score MMSE ± SD 25.9 ± 3.2 26.3 ± 2.9 25.5 ± 3.5 0.22
Mean score AKT ± SD 50.7 ± 6.5 51.1 ± 4.7 50.1 ± 8.1 0.51
There was a signiﬁcant difference SGS versus standard group (P<0.05) in HbA1c and body mass index (BMI).
Quality of metabolic control (HbA1c, HPLC Diamat
R ,
Munich,normalrange:4.4–6.3%)wasmeasuredbytheInsti-
tute of Clinical Chemistry, University of Jena, Germany.
Additionally, we assessed diabetes duration, duration of
insulin therapy, insulin dose and medication.
Treatment satisfaction and diabetes knowledge were
assessedusingstandardisedquestionnaires[5,8,9].Toassess
patient skill in diabetes self-management (correct insulin
injection, self-monitoring), a detailed standardised handling
test (maximum score 23 points [10]) was performed. This
test was only performed on patients who injected insulin
themselves. All of these 110 participants completed the
handling tests immediately after the structured education
(t1).
A neuropsychological examination was performed to
assess cognitive function including the MMSE [11], and the
age concentration test AKT [12]. The MMSE score of 24–
30 points reﬂects no cognitive dysfunction, 18–23 points
mild cognitive impairment and below 18 points moderate-
to-severecognitiveimpairment.TheAKTisavalidatedGer-
man symbol test for cognitive function developed for older
people using a sum score (maximum 55 points).
Diabetes treatment: at enrolment, 10 (6.7%) patients started
on insulin therapy, 107 (70.8%) patients were already on
insulin therapy and 34 were on insulin and oral antidiabetic
drug therapy (22.5%). There were no signiﬁcant differences
in treatment strategies comparing SGS and standard group
participants prior to the DTTP. The mean insulin dose was
42 IU (insulin units)/day (6–140). A total of 77 (49.7%)
patientshadalreadyparticipatedinastructuredDTTPbefore
[22 patients (14.2%) in a DTTP without insulin therapy, 54
patients (34.8%) in a DTTP for insulin-treated patients, no
data regarding the type of DTTP given for one patient].
Patient characteristics are shown in Table 1. The mean age
of the 155 enrolled patients was 76.2 ± 6.3 years showing
a mean HbA1c level of 8.0 ± 1.4% and a median diabetes
duration of 12.5 (0–56.5) years.
Comorbidity and acute complications such as
symptomatic/severe hypoglycaemia or coma were assessed
by patient self-report and medical records. Peripheral
polyneuropathy was examined according to Young et al.
[13], nephropathy according to creatinine clearance [14] and
retinopathyaccordingtotheETDRScriteria[15].Forty-nine
per cent of the 155 patients had at least one late complica-
tion(retinopathy,nephropathyorperipheralfootulceration).
Retinopathy was present in 12.3% of the patients, peripheral
polyneuropathy in 34.8% and nephropathy in 16.1%. Of the
155 patients, 69.2% had at least one geriatric syndrome such
as urinary incontinence, cognitive decline, reduced mobility
or a history of falls in the past 2 years. The remaining 21.9%
suffered from two geriatric syndromes and 8.9% from three
or more geriatric syndromes. The most common geriatric
syndrome was urinary incontinence in 73.3% of the patients.
Coronary heart disease was present in 37.7% of the patients,
previous stroke in 15.1% and arterial hypertension in 74.1%.
At enrolment, patients were asked a screening question for
depression [16]. Thirty-one patients (20%) reported feelings
of sadness and depression.
Statistical analysis
Statistical analysis was performed with the software SPSS
R 
(Statistical Package for Social Science, SPSS, Chicago, IL,
USA).Normallydistributedvalueswereregisteredasmean±
standarddeviation,notnormallydistributedvaluesasmedian
andrange.Comparisonswereevaluatedwithchi-squaretests.
Student’s t-test and Wilcoxon tests were used to compare
the mean. The signiﬁcance was set at P<0.05. Two-sided
testing was used throughout. Associations were evaluated
using Pearson’s correlations for normally distributed values.
Exploratory multiple regression analysis was performed.
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Table 2. Results of patients completing the follow-up visit 6 months after participation in the DTTP
SGS Standard P-value (SGS vs. standard group)
Number of patients 65 54 –
.......................................................................................................................................
Diabetes knowledge and results in handling test
Diabetes knowledge, points ± SD, t0 7.4 ± 2.3 6.8 ± 2.8 0.22
Diabetes knowledge, points ± SD, t1 8.7 ± 2.6 8.7 ± 2.7 0.93
Diabetes knowledge, points ± SD, t2 8.4 ± 2.3 8.3 ± 2.6 0.85
P-value t1 versus t0 0.004 <0.001 –
P-value t2 versus t1 0.011 0.001 –
Handling test, points ± SD, t1 16.7 ± 3.8 15.5 ± 4.6 0.89
Handling test, points ± SD, t2 16.6 ± 3.9 15.4 ± 5.0 0.21
  points in the handling test ± SD 0.1 ± 4.6 0.7 ± 6.0 0.61
P-value t2 versus t1 0.93 0.49 –
Metabolic control
Mean HbA1c% ± SD, t1 8.3 ± 1.5 7.7 ± 1.3 0.02
Mean HbA1c% ± SD, t2 7.7 ± 1.5 7.6 ± 1.5 0.85
P-value t2 versus t1 0.01 0.97 –
  mean HbA1c% 0.5 ± 1.5 0.01 ± 1.5 0.08
Treatment satisfaction
Median treatment satisfaction, points (range), t0 28 (6–38) 28 (13–36) 0.81
Median treatment satisfaction, points (range), t2 31 (13–36) 31 (14–36) 0.97
Hyperglycaemia-related self-reported burdens, points (range), t0 3 (0–6) 3 (0–6) 0.49
Hyperglycaemia-related self-reported burdens, points [range], t2 3 (0–6) 2 (0–6) 0.01
Incidences of acute complications
Symptomatic hypoglycaemia, events/patient/year, t0 0.63 0.79 0.44
Symptomatic hypoglycaemia, events/patient/year, t2 0.47 0.92 0.009
Severe hypoglycaemia, t0 0.13 0 0.13
Severe hypoglycaemia, t2 0.06 0 0.50
Foot ulceration, t0 0.09 0 0.25
Foot ulceration, t2 0.03 0.15 0.17
Results
One hundred nineteen of 155 patients (78%) were re-
examined6monthsaftertheDTTP(mean0.64±0.28years).
Eightpatientsdiedduringfollow-upvisits(threeoutofSGS,
ﬁve out of the standard group; causes of death in three cases:
heart failure, stroke and myocardial infarction; in ﬁve cases
cause of death was unknown, mean HbA1c at enrolment
7.1 ± 1.0%). Patient characteristics at follow-up (t2) are pre-
sented in Table 1.
Primary outcomes
Although on average the SGS participants began the pro-
grammewithslightlyhigherHbA1cvalues(SGSvs.standard
group: 8.3 ± 1.5% vs. 7.7 ± 1.3%) due to group randomisa-
tion,theHbA1cdecreasewassigniﬁcantafterSGSeducation
(t1 vs. t2: 8.3 ± 1.5% vs. 7.7 ± 1.5%, P = 0.01), while stan-
dardgroupparticipantsmaintainedtheirbaselinelevel(7.7±
1.3 vs. 7.6 ± 1.5, n.s., Table 2).
Skills in diabetes self-management were similar in both
groups (handling test SGS vs. standard: 16.6 ± 3.9 points vs.
15.4±5.0points,n.s.).Thehandlingtestwasperformedonly
on patients independent of third-party assistance regarding
their insulin therapy. The total number of patients who were
able to inject insulin by themselves was higher after the SGS
DTTP(SGSvs.standard:88.2%vs.75.8%).Sixmonthsafter
teaching, there were still more patients from the SGS group
able to perform precise insulin injection (SGS vs. standard:
83.1%vs.72.2%).Inbothgroupstogether,90%oftheelderly
patients were able to perform correct insulin injection and
85% correct self-monitoring of blood glucose. A total of
96.4% of the patients knew the correct timing and area of
insulin application after the structured DTTP, but only 63%
of the geriatric patients were able to remember the name and
type of their insulin.
Secondary outcomes
Diabetes knowledge increased signiﬁcantly in both groups
after the DTTP (SGS t0 vs. t1: 7.4 ± 2.3 points vs. 8.7 ±
2.6 points, P = 0.004; standard t0 vs. t1: 6.8 ± 2.8 vs. 8.7
± 2.7 points, P = 0.001. Six months after the structured
DTTP (t2), a slight decrease in diabetes knowledge in both
groups was measured, but compared to baseline knowledge,
was still at a signiﬁcantly higher level (SGS t0 vs. t2: 7.4 ±
2.3 points vs. 8.4 ± 2.3 points, P = 0.011; standard: 6.8 ±
2.8 points vs. 8.3 ± 2.6 points, P = 0.001). Overall treat-
ment satisfaction was equal in both groups at the t0 and
t2 visits [SGS vs. standard t0: 28 (6–38) points vs. 28 (13–
36) points, n.s.; t2: 31 (13–36) points vs. 31 (14–36) points,
n.s.]. However, patients who participated in the SGS DTTP
reported a signiﬁcantly lower number of problems due to
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hyperglycaemia 6 months after the DTTP [SGS vs. standard
t2: 3 (0–6) points vs. 2 (0–6) points, P = 0.01].
Acute complications
The number of incidences of symptomatic hypogly-
caemia was signiﬁcantly lower in the SGS group (SGS
vs. standard group t2: 0.47 events/patient/year vs. 0.92
events/patient/year, P = 0.009). The numbers of incidences
ofseverehypoglycaemia(needofi.v.glucoseori.m.glucagon
injection) and incidences of foot ulceration were comparable
inbothgroups.Therewerenocasesofcomaduringthestudy
period.
Correlation analysis
There was a signiﬁcant negative correlation of skills in dia-
betes self-management with age (r =− 0.21; P = 0.02), num-
ber of geriatric syndromes (r =− 0.26; P= 0.005) and points
in AKT (r = 0.20; P = 0.04). There was a correlation of
the performance in diabetes knowledge test (r = 0.19; P =
0.03) with the performance in the MMSE and with diabetes
duration (r = 0.19; P = 0.04), but not with age. In multi-
variate analysis, the points in the MMSE prior to the DTTP
(P=0.02)andtheabsenceofgeriatricsyndromes(P=0.009)
were associated with better diabetes self-management skills
after the DTTP (other factors included in the model: age,
AKT score).
Discussion
This study demonstrates that the new SGS DTTP promotes
a signiﬁcant HbA1c decrease, reduces incidence of acute
complications, improves diabetes knowledge and enhances
diabetes self-management skills.
Although the study was performed as a randomised trial,
there are limitations due to differences in HbA1c levels at
enrolment. The randomisation of study participants was per-
formed using group randomisation lists. HbA1c was mea-
sured in one central laboratory at the University of Jena to
avoid bias. As other variables were well randomised, we sug-
gest that the reason for the differences in HbA1c is the small
sample size. According to the sample size calculation, 102
patients per group should have been randomised to obtain
a signiﬁcant HbA1c decrease, but due to limited ﬁnancial
resources and difﬁculties in recruitment of older geriatric
patients facing multi-morbidity, the study had to be stopped
before. In our opinion, both groups tend to stay close to the
target levels and differences in baseline HbA1c should not
strongly affect the study results. The adjustment of HbA1c
reduction for baseline HbA1c in this study cohort was not
indicated due to its small variance.
Both training groups had a favourable effect on diabetes
knowledge. The present study demonstrates that patient-
oriented education is suitable to enhance diabetes self-
management skills in the older patients. Moreover, the SGS
DTTP needs fewer resources (e.g. time expense). Its didac-
tic particularities reduce common barriers for the diabetes
education of older patients.
Prevention of frailty, cognitive decline or immobility not
only reduces the need for care by the elderly, but increases
quality of life as well—and clearly promotes motivation for
better diabetes control [17–19]. Furthermore, epidemiologi-
caldataindicatethatseriousqualityissuesinthetreatmentof
elderly people with diabetes will indeed challenge health care
providers in the near future, because of the increasing life
expectancy and incidence of diabetes in older age [20, 21].
The participation in structured education programmes
is associated with improvement in quality of life in elderly
patients with T2DM [22]. Elderly diabetic patients showed a
slight but not signiﬁcant increase in treatment satisfaction in
both groups, but SGS participants showed less personal anx-
iety due to hyperglycaemia even though they showed higher
HbA1c levels at enrolment. One conclusion of this study is
that geriatric patients with diabetes, even with mild cognitive
impairment and depression, can beneﬁt from a DTTP con-
cerningobjectiveoutcomesaswellasself-reportedmeasures,
as shown by the reduction of fear of hypoglycaemia.
There is increasing evidence that patient-oriented educa-
tion is beneﬁcial with regard to quality criteria and patient
outcomes [1, 23, 24]. Patient education enables patients with
diabetestoperformtreatmentstrategiesontheirownauthor-
ity [22, 25]. Several studies have found that younger patients
with diabetes who have participated in a structured DTTP
performmoreaccurateblood–glucoseself-monitoring,show
improved diabetes knowledge, improved metabolic control
and increased diabetes-related quality of life and suffer fewer
acute complications [1, 3, 26].
The innovative training programme SGS addresses a cur-
rent and rapidly growing problem, and ﬁlls an existing gap
centring on the geriatric patient with diabetes.
Although the average diabetes duration in this study was
nearly 14 years, only half of the participants had previously
participated in any structured diabetes training programme.
Thebarrierstohealthcarearestillmoreforgeriatricpatients.
Increasingly, patients with diabetes live to an advanced age
accompanied by a variety of impairments and geriatric syn-
dromes [17–19] as well as multi-morbidity. Besides the pre-
vention of catabolic symptoms or acute complications, the
new DTTP SGS embraces a practical approach focusing on
the maintenance of autonomy and deﬁnition of individual
therapeutic goals to assure well-being of the older patients
concerningalsotheinteractionbetweendiabetesandgeriatric
syndromes [4, 20].
The SGS is a new approach to education of the geriatric
patient, focusing on resources, accepting deﬁcits and lower-
ing barriers to participation in modern treatment strategies
for elderly patients.
Key points
 The SGS programme is a new structured DTTP for geri-
atric patients with diabetes mellitus considering the lim-
ited resources and learning capabilities of older people.
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 The SGS programme focuses on the maintenance of
autonomy of older people and is effective in transfer-
ring both diabetes knowledge and diabetes management
to geriatric patients. Its effectiveness has been proven
within the present randomised controlled trial.
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Prevalence of ﬂexible bronchoscopic removal of
foreign bodies in the advanced elderly
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Abstract
Objectives: to deﬁne the likelihood and establish the overall safety and effectiveness of ﬂexible bronchoscopy in the removal
of foreign bodies in the advanced elderly compared to those younger.
Design: a retrospective case–control analysis.
Setting: tertiary care academic hospital.
Population: 7,089 adults (age >18 years), including 949 (15%) advanced elderly (age >75 years), who underwent ﬂexible
bronchoscopy between January 1995 and June 2007.
Measurements:inthosepatientswithforeignbodyaspiration(FBA)(n=20),acomparisonofmultipleclinicalcharacteristics
based on deﬁned age groups (group 1, age <75 years and group 2, age >75 years) was performed.
Results: FBA requiring bronchoscopic removal was greater than three and a half times more likely in patients aged >75 years
compared to those younger (OR 3.78, CI 1.4–10: P <0.05). Flexible bronchoscopy was 87.5% effective in the removal of
foreign bodies in the advanced elderly and associated with no increase in adverse events.
Conclusion: bronchoscopic removal of foreign bodies is more likely in the advanced elderly when compared to those
younger. This implies that this population may be most at risk. Flexible bronchoscopy is a safe and effective initial diagnostic
and therapeutic approach in this age group.
Keywords: foreign body aspiration, elderly, advanced elderly, ﬂexible bronchoscopy
Introduction
Foreign body aspiration (FBA), deﬁned as the introduction
of a large particulate material into the tracheobronchial tree,
is a rare event that increases with age [1–4]. Despite this age
association, the risk of FBA in older adults remains poorly
deﬁned. The presence of cerebrovascular disease, heart
396